Topics

Incyte Reports 2019 First Quarter Financial Results and Provides Updates on Key Clinical Programs

07:00 EDT 30 Apr 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Total revenues of $498 million (+30% vs Q1 2018) and total product-related revenues of $458 million (+20% vs Q1 2018) for the quarter ended March 31, 2019 Jakafi® (ruxolitinib) revenues of ...

Other Sources for this Article

Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com

Investors
Michael Booth, DPhil
+1 302 498 5914
mbooth@incyte.com

NEXT ARTICLE

More From BioPortfolio on "Incyte Reports 2019 First Quarter Financial Results and Provides Updates on Key Clinical Programs"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...